Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

BACKGROUND: Immune checkpoint inhibitor therapy has changed the standard drug therapy for relapsed or advanced non-small cell lung cancer; its efficacy is well-recognized by pulmonary physicians, oncologists, and thoracic surgeons. Nivolumab, one of the anti-programmed cell death 1 antibodies, was t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Med Case Rep
Hlavní autoři: Hasegawa, Takeo, Ozaki, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Fukuhara, Mitsuro, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6813076/
https://ncbi.nlm.nih.gov/pubmed/31647029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-019-2245-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky